Clinical outcomes: to be a surrogate or not to be ...? by Cameron, David
Introduction
Clinical trials remain the bedrock of the introduction of new
therapies for patients with cancer. Over the past 30 years
there have been enormous improvements in outcomes for
patients with breast cancer, based largely (but not exclu-
sively) on the widespread implementation of the results of
randomized trials. Widespread use of screening mammo-
graphy, breast conservation, adjuvant hormonal therapy,
adjuvant chemotherapy and, most recently, adjuvant
trastuzumab have all been based on the results of well
designed clinical trials. All of these interventions have been
shown to either improve survival or, in the case of breast
conservation, maintain survival despite less radical surgery.
For most women with early breast cancer, it is the avoidance
of the death sentence they feel hangs over them when they
are first diagnosed with cancer, that is the most important
reason why they undergo these treatments.
Clinical research in breast cancer remains as active as ever,
with newer interventions being tested in ever larger and/or
more complex trial designs. Many studies may not be
designed to test questions about overall survival, with recent
studies also addressing tolerability, issues of limited
resources and, increasingly, means to target treatments to
the subgroups of patients who really benefit from the specific
therapy. The goal of studies that aim to optimize treatment
may not be the same for the researcher and the patient.
However, most would agree that it would be ideal if we could
reduce the diagnosis of breast cancer to one that had the
same implications as being diagnosed with a ‘touch of blood
pressure’, namely the concept that although a few patients
may still suffer unwanted consequences of the diagnosis, for
the vast majority the implication is the necessity to undergo
relatively nontoxic treatment that effectively prevents
recurrence. To this end, many trials are now designed to
address different primary end-points from the traditional one,
still much beloved of the US Food and Drug Administration,
of overall survival (OS).
Surrogate end-points: fit for purpose?
Even when improvements in OS are the ultimate aspiration of
a study, it is common for reasons of timeliness to make
another end-point the primary determinant of success. For
adjuvant trials, the use of disease-free survival (DFS) is an
accepted surrogate because, to date, mature follow up of
both individual trials and their meta-analyses have
consistently confirmed that improvements in DFS
subsequently translate into firm improvements in OS. For
advanced disease studies, time to disease progression (TTP)
is frequently used, but in fact this much less commonly
precedes clear improvements in OS, although a few notable
exceptions exist (use of trastuzumab and in some studies
involving taxanes). The reasons for this divergence are not
entirely clear, because in both adjuvant and advanced
disease studies the possibility exists of a loss of effect of the
earlier use of a novel intervention as a consequence of its use
after relapse/progression. Furthermore, most successful
adjuvant interventions are designed on the basis of a positive
improvement in TTP in an advanced disease study, and
survival gains in early disease can often be seen despite the
lack of gains in OS in a comparable advanced disease study.
However, this may not be as big an issue as it first appears
because it highlights an important question; when should a
trial be designed simply to produce the data required to
justify the testing of an intervention in early disease, and when
should it be designed to benefit the patient population in
whom it is actually being tested?
In advanced disease, although an improvement in survival
remains the over-arching wish of most patients, when this is
not likely there nevertheless remain important improvements
that are highly clinically relevant. There are good data that
improvements in quality of life and/or reduction in symptoms
correlate with tumour response, so that where patients are
very symptomatic, demonstration of an increased response
rate is a worthwhile gain, provided that this does not come at
the cost of major toxicity. In contrast, for many women with
more indolent, relatively asymptomatic disease, absence of
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© 2007 BioMed Central Ltdprogression may be the primary goal. It is interesting to note,
therefore, that patients with stable disease for at least
6 months on hormonal therapy often have similar OS to those
whose disease actually shrinks on therapy, justifying the use
of TTP and/or clinical benefit as the primary end-point for
many such studies.
Conventional drug development model
For cytotoxics, the phase I-II-III development sequence (as
shown in Figure 1) was in fact based on the experience that
the maximum tolerated dose (MTD) in phase I often turned
out to be an effective and tolerated dose in early stage
disease. However, for cytotoxics the identification of a dose
on the basis that it caused an acceptable level of cytotoxicity
in normal tissues, which could then cause a desirable level of
cytotoxicity in malignant tissues, is perhaps not a great
surprise! All patients contribute toward the toxicity end-point
in a conventionally designed phase I study, and so it is a
relatively efficient way to reach the dose level likely to deliver
efficacy if it exists. In contrast (Figure 2), the way in which we
might determine a maximum biologically effective dose could
be more difficult.
Therefore, in a translational phase I or dose-finding study, in
which there is a good surrogate normal tissue with little
variation in sensitivity (the biological equivalent of the bone
marrow or gastrointestinal mucosa for a classical cytotoxic),
this may not be a problem. When the surrogate end-point
used is in the tumour, however, we have the problem that we
will have to increase the number of patients at each dose
level by a factor related to the proportion of patients with
sensitive tumours. For example, if only half of the patients
have sensitive disease, then in a cohort of three patients (the
classic phase I design) there is a one in eight (0.125) chance
that no biological effect will be seen at one level simply
because all three tumours were totally resistant; across three
active dose levels the chance that we will have one cohort
with no responses becomes 0.29, or almost one in three! If
one then considers the risk that a biologically maximally
effective dose is identified because no responses are seen at
a higher dose level, it becomes apparent that this can happen
not infrequently. Hence, if only half of the patients have
sensitive disease, then one will need at least five patients per
dose cohort to have less than a 5% chance of seeing no
response at a biologically active dose, a figure that rises as
the proportion of responders falls.
Presurgery systemic therapy
Perhaps the area of clinical research where there is most
interest in surrogates is in the use of systemic therapy before
surgery. Essentially two models exist: the short ‘preoperative’
course, designed not to deliver systemic benefit but only
short-term biological changes in the breast cancer; and the
longer ‘neoadjuvant’ or ‘primary systemic’ therapy, in which
clinical changes in the primary tumour are the goal, using
drugs that deliver systemic benefits. It became clear over
many years that when patients are treated with 3 to 6 months
of chemotherapy, those patients who have no residual
invasive disease in the primary tumour and/or ipsilateral
axillary lymph nodes have the best long-term outcome. It was
anticipated, therefore, that where additional therapy given
before surgery increased the proportion of patients achieving
such pathological complete responses (pCR), this would lead
to gains in long-term outcome. To date, that has not been
confirmed, in particular in the National Surgical Adjuvant
Breast and Bowel Project (NSBAP) B-18 trial, in which
addition of docetaxel before surgery doubled the proportion
of patients achieving pCR but made no significant difference
to the distant DFS. However, it remains true that on the one
Breast Cancer Research    Vol 9 Suppl 2 Cameron
Page 2 of 3
(page number not for citation purposes)
Figure 1
Traditional drug development - defining maximum tolerated dose
(MTD) using advanced disease as a model.
PHASE 1 To identify dose for Phase II
Myelotoxicity surrogate for cytotoxicity
ALL patients contribute
Cohorts of 3 (or more) patients with increasing doses 
until 2/6 have dose-limiting toxicity (defines MTD)
PHASE 2 To confirm efficacy sufficient for Phase III testing
Response surrogate for efficacy
Enrolled patients must have tumours which are easily measurable
May be randomised to produce “internal” control
PHASE 3 To confirm efficacy as compared to standard of care
Time to progression is the measure of efficacy
ALL patients contribute to efficacy and toxicity
Patient symptomatic benefit not main end-point
Figure 2
Biological drug development - defining biologically effective dose
(BED) using advanced disease as a model.
PHASE 2 To confirm efficacy sufficient for Phase III testing
Clinical response surrogate for efficacy
Enrolled patients must have tumours which are easily measurable
May need to be randomised to produce “internal” control
May need two different doses to “confirm” dose from phase I
PHASE 3 To confirm efficacy as compared to standard of care
Time to progression is the measure of efficacy
ALL patients contribute to efficacy and toxicity
Patient symptomatic benefit not main end-point
PHASE 1 To identify dose for Phase II
Tumour biological changes surrogate for efficacy
Only accessible tumours with drug sensitivity contribute
Cohorts of at least 3 x                              with increasing
doses until no more increase in response  (defines BED)
tumours f oe v i t i s n e s proportion
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hand the addition of taxanes and/or trastuzumab to
neoadjuvant chemotherapy does increase the proportion of
patients achieving pCR, and on the other that the addition of
those same agents to postoperative adjuvant therapy does
lead to improved OS. Therefore, pCR would appear to be a
surrogate predictor of a more effective adjuvant therapy; what
it does not yet appear to do is to identify the precise patients
who will benefit from the therapy!
For patients given short-term exposure to a drug before
surgery, there is interest in understanding what biological
changes in that context mean for long-term clinical benefit. To
date, no study has assessed the prognostic or predictive
implications for a specific biological change induced by a
short-term exposure to therapy before routinely timed surgery.
However, we do have data on the biological changes seen
after 2 weeks of exposure to tamoxifen and/or anastrazole, in
patients who then continued on therapy, had surgery after a
further 10 weeks of therapy and then were encouraged to
continue on the same hormonal therapy in the adjuvant
setting. In this setting, it was clear that those patients whose
tumours had the lowest rate of proliferation at 2 weeks had
the lowest rate of recurrence. These data would appear to
indicate that where a tumour has a very low proliferation rate
(either intrinsically or more probably because hormonal
therapy has reduced it), there is a low rate of relapse, at least
over the first few years. It does need to be borne in mind that
where patients are given adjuvant tamoxifen, at least in the
older trials that make up the Oxford Overview, the majority of
relapses occur after the 5 years of therapy, so that the low
proliferating tumours might just be the ones that take longer
to relapse. However, it seems reasonable to take the view
that reduction in proliferation after 2 weeks of hormonal
therapy is a surrogate for identifying a lower rate of relapse
during the first few years after surgery, and there is a high
chance that therapies that are better at doing this (as was
shown in the above study for the aromatase inhibitor
anastrazole) will be better at preventing relapse during the
first few years (as ATAC [Arimidex, Tamoxifen Alone or
Combination] has shown).
Conclusion
For most patients, and for most trials in early disease, a
treatment that cures more people, or one that cures just as
many with fewer unwanted side effects, is the desired goal
and no surrogate can really replace this. Use of DFS as the
first end-point, because it has consistently been validated as
predating improvements in OS, is perfectly acceptable, as
long as studies with novel interventions continue to collect
the follow-up data to demonstrate that this linkage applies to
newer biological interventions just as it does for conventional
treatments.
However, for many studies there is a good clinical justification
for using other end-points that meet the needs of the patient
population being studied; end-points such as TTP, response
rate, and clinical benefit rate are therefore not just to be seen
as surrogates but as the most appropriate end-point for that
trial.
There remains the question as to when a surrogate is a valid
end-point for subsequent improvements in DFS and/or OS.
Two obvious candidates in the field of preoperative or
neoadjuvant therapy are falls in proliferation in patients
treated with primary (short-term or long-term) endocrine
therapy, or the proportion of patients achieving pCRs to
neoadjuvant chemotherapy. Both appear to be reliable, at
least most of the time, but neither has yet been shown to
have an ideal level of discrimination between agents that can
and cannot lead to changes in ultimate outcomes. This lack of
clear linkage could in fact be because some of the agents
tested in these studies have themselves not delivered a large
enough improvement in efficacy to confirm the link with DFS
and/or OS.
Surrogates must be proven to be able to take the place of the
real end-point in question, and to date, this linkage is only
really established for some treatments. For new biological
agents this is even less certain, although the success of
trastuzumab suggests that we can have confidence that a
model developed for untargeted cytotoxics, and loosely
targeted hormonal therapies, may work out for many newer
agents. However, in my view, this cannot be taken for
granted, and the relevant longer term follow up is necessary
in a generation of trials of newer agents with a size such that
primary end-points are met within a short time of closure to
accrual.
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